All posts by: Michael Zand

About Michael Zand

Roche’s immunotherapy combo receives FDA priority review – BioPharma-Reporter.com

Continue reading

2018-05-09 NEWS

BioPharma-Reporter.com

Roche’s immunotherapy combo receives FDA priority review
BioPharma-Reporter.com
Roche’s immunotherapy combination has received priority review after Phase III trial results showed potential to provide significant survival benefit in the initial treatment of NSCLC. The US Food and Drug Administration (FDA) has granted Roche

Continue reading

2018-05-09 NEWS

MD Magazine

Hossein Ameri, MD: Will CRISPR Fix Retinitis Pigmentosa?
MD Magazine
Thomas Castles. @Thomas_Castles. Currently, patients with retinitis pigmentosa (RP) are limited to receiving retinal prosthesis. It’s the only approved treatment for the condition, and is only suitable for patients with advanced disease and profound